HHT drug trial pulled before it even started
Disease control
Terminated
This study was designed to test a new drug called TER-1754 for people with hereditary hemorrhagic telangiectasia (HHT), a condition that causes abnormal blood vessels and frequent nosebleeds. The trial was withdrawn before enrolling any participants, so no results are available. …
Phase: PHASE1 • Sponsor: Terremoto Biosciences Inc. • Aim: Disease control
Last updated May 17, 2026 05:53 UTC